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dence of vasospasm, defined as an inner artery diameter re-
duction of major intracranial arteries  ≥ 34% based on cathe-
ter angiography, was compared between each treatment 
group. Cerebral infarction due to vasospasm at 6 weeks and 
patients’ outcome at 3 months was also compared.  Results: 
Among 181 enrolled patients, 158 completed the study and 
were analyzed. The incidence of vasospasm up to day 14 af-
ter aSAH onset was 80.0% in the placebo group (95% CI 67.0–
89.6), 38.5% in the 5 mg/h clazosentan group (95% CI 25.3–
53.0), and 35.3% in the 10 mg/h clazosentan group (95% CI 
22.4–49.9), indicating that the incidence of vasospasm was 
significantly reduced by clazosentan treatment (placebo vs. 
5 mg/h clazosentan,  p < 0.0001; placebo vs. 10 mg/h clazosen-
tan,  p < 0.0001). The occurrence of cerebral infarction due to 
vasospasm was 20.8% in the placebo group (95% CI 10.8–
34.1), 3.8% in the 5 mg/h clazosentan group (95% CI 0.5–
13.2), and 4.2% in the 10 mg/h clazosentan group (95% CI 
0.5–14.3), indicating that clazosentan significantly reduced 
the occurrence of cerebral infarctions caused by vasospasm 
(placebo vs. 5 mg/h clazosentan,  p = 0.0151; placebo vs. 10 
mg/h clazosentan,  p = 0.0165). The overall incidence of all-
cause death and/or vasospasm-related morbidity/mortality 
was significantly reduced in the 10 mg/h clazosentan group 
compared with the placebo group ( p = 0.0003).  Conclusion: 
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 Abstract 
 Background: Clazosentan has been explored worldwide for 
the prophylaxis of cerebral vasospasm after aneurysmal 
 subarachnoid hemorrhage (aSAH). In a dose-finding trial 
 (CONSCIOUS-1) conducted in Israel, Europe, and North 
America, clazosentan (1, 5, and 15 mg/h) significantly re-
duced the incidence of cerebral vasospasm, but its efficacy 
in Japanese and Korean patients was unknown. We conduct-
ed a double-blind comparative study to evaluate the occur-
rence of cerebral vasospasm in Japanese and Korean pa-
tients with aSAH.  Methods: The aim of this multicenter, dou-
ble-blind, randomized, placebo-controlled, dose-finding 
phase 2 clinical trial, was to evaluate the efficacy, pharmaco-
kinetics, and safety of clazosentan (5 and 10 mg/h) against 
cerebral vasospasm after clipping surgery in Japanese and 
Korean patients with aSAH. Patients aged between 20 and 
75 years were administered the study drug within 56 h after 
the aneurysm rupture and up to day 14 post-aSAH. The inci-
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These results suggest that clazosentan prevents cerebral va-
sospasm and subsequent cerebral infarction, and could 
thereby improve outcomes after performing a clipping sur-
gery for aSAH in Japanese and Korean patients. 
 © 2017 The Author(s)
Published by S. Karger AG, Basel 
 Introduction 
 Prevention of cerebral vasospasm is one of the most 
critical factors to improve the outcome of clipping sur-
gery in patients with aneurysmal subarachnoid hemor-
rhage (aSAH). Once cerebral vasospasm develops, pa-
tients experience delayed ischemic neurological deficit 
(DIND) in 17–40% of cases, half of which result in cere-
bral infarction  [1] . Nimodipine has been used worldwide 
for improvement in neurological outcomes, and a vari-
ety of drugs such as fasudil hydrochloride (Rho kinase 
inhibitor) and sodium ozagrel (thromboxane A2 syn-
thase inhibitor) have been used for the prevention of va-
sospasm  [2, 3] . However, despite the use of these drugs, 
it is still difficult to prevent cerebral vasospasm efficient-
ly. It is therefore necessary to develop an alternative pro-
phylactic agent against cerebral vasospasm  [2] . 
 In aSAH, the release of oxyhemoglobin-derived endo-
thelin from red blood cells is believed to contribute signifi-
cantly to the development of cerebral vasospasm due to its 
potent, long-lasting vasoconstrictor effects  [4–6] . In light of 
the potential role of endothelin in vasospasm, clazosentan – 
an endothelin-A receptor antagonist – has been investigat-
ed worldwide as a prophylactic agent to prevent cerebral 
vasospasm  [7–9] . The “Clazosentan to overcome neurolog-
ical ischemia and infarction occurring after subarachnoid 
hemorrhage” (CONSCIOUS)-1 trial demonstrated that the 
incidence of cerebral vasospasm was significantly reduced 
by clazosentan in Israeli, European, and North American 
patients [7] . However, the efficacy of clazosentan in Japanese 
and Korean patients was unknown, since Japan and Korea 
were not included. Therefore, we conducted a phase-2 
dose-finding trial to evaluate the use of clazosentan in 
 Japanese and Korean patients. Clazosentan was adminis-
tered at doses of 5 and 10 mg/h, which are different from the 
doses used in the CONSCIOUS-1 trial to account for the 
smaller body sizes of Asian patients compared with Euro-
pean and American patients  [10] . 
 Methods 
 Study Design 
 The study was a multicenter, double-blind, randomized, place-
bo-controlled, dose-finding, phase-2 trial to investigate the occur-
rence of cerebral vasospasm in patients with aSAH who had un-
dergone clipping surgery. Patients were administered either 5 or 
10 mg/h clazosentan or a matching placebo ( Fig. 1 ). The study was 
conducted by specialized neurosurgeons in 22 centers in Japan and 
10 centers in South Korea. 
 The study was approved by the Institutional Review Boards of 
each center and was conducted in accordance with the Declaration 
of Helsinki and Good Clinical Practice guidelines (Trial Registra-
tion: Japan Pharmaceutical Information Center Clinical Trial 
 Information [JapicCTI-152889]). Prior to the start of the trial, phy-
sicians fully explained the methods and objectives of the trial to 
patients and/or their legal guardians, and obtained voluntary writ-
ten consent for each patient.
 Population 
 Participating patients were Japanese or Korean individuals be-
tween the ages of 20 and 75 years. The main inclusion criteria were 
classification as group 3 on the Fisher scale and long axis of sub-
arachnoid hemorrhage of  ≥ 20 mm or extending to both hemi-
spheres of the brain on the preoperative CT scan. The main exclu-
sion criteria were as follows: being classified as World Federation 
of Neurosurgical Surgeons (WFNS) grade 5; serious intraoperative 
complications such as large territorial cerebral infarction ob-
served; hemiplegia or disturbance of consciousness continuing for 
 ≥ 12 h after clipping surgery;  experiencing treatment-resistant hy-
Screening
and
clipping
Placebo
Clazosentan 5 mg/h
Clazosentan 10 mg/h
Screening
DSA, CT
24–48 h
post CT
Day 9±2
DSA
Week 6
CT, morbidity/
mortality
Week 12
GOSE, mRS
MMSE
Day 14 after aSAHaSAH
Within 56 h after aSAH Treatment period Follow-up
12 weeks
after aSAH
 Fig. 1. Study design. aSAH, aneurysmal 
subarachnoid hemorrhage; DSA, digital 
subtraction angiography; GOSE, Glasgow 
Outcome Scale-Extension; mRS, modified 
Rankin Scale; MMSE, Mini-Mental State 
Examination. 
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potension; severe heart failure; aspiration pneumonia or pulmo-
nary edema; a serum creatinine level of  ≥ 2.0 mg/dL; a total biliru-
bin level of more than twice the upper limit of the facility’s refer-
ence value; and evidence of liver cirrhosis. We did not include 
patients in groups 1, 2, and 4 on the Fisher group.
 Study Intervention 
 Clazosentan or placebo administration was started within 56 h 
after the onset of aSAH and continued up to day 14 after the onset 
of aSAH. 
 Concomitant use of fasudil hydrochloride (not approved for 
use in South Korea), sodium ozagrel, nizofenone fumarate (release 
canceled in South Korea), ticlopidine hydrochloride (not approved 
for use in South Korea), intravenous (i.v.) nimodipine (not ap-
proved for use in Japan), i.v. nicardipine, or statins (acceptable if 
administration was started before onset of aSAH) was prohibited. 
However, no restriction was placed on the use of oral nimodipine, 
which is approved for use in South Korea.
 Clinical Assessment and Radiology 
 Digital subtraction angiography (DSA) and CT imaging were 
conducted for all patients ( Fig. 1 ). After anonymization, images 
were submitted for evaluation by an Image Review Committee 
(IRC) comprising 5 radiology or neurosurgical specialists. The 
IRC members measured the inner artery diameters of the proximal 
blood vessels, and assessed the qualitative severity of cerebral va-
sospasm for distal blood vessels based on an inner artery reduction 
<34% (none to mild), 34–65% (moderate), and  ≥ 66% (severe; 
 Fig. 2 ). Based on previous observations, the presence and severity 
of vasospasm according to these categories correlated with the de-
velopment of brain ischemia and cerebral infarction  [11, 12] . Any 
2 IRC members assessed the same case independently and if there 
was a discrepancy in their findings, the committee chairperson 
gave a final judgment. Trans-cranial Doppler ultrasound was not 
used for the assessment of vasospasm in this study.
 Efficacy 
 The primary endpoint was a comparison of the occurrence of 
moderate or severe cerebral vasospasm up to day 14 after aSAH 
onset between the placebo and clazosentan groups. The secondary 
endpoints were the occurrence of newly formed cerebral infarc-
tions associated with vasospasm within 6 weeks after aSAH onset, 
and assessments of Glasgow Outcome Scale-Extended (GOSE), 
modified Rankin Scale (mRS), and Mini-Mental State Examina-
tion (MMSE) at 12 weeks after aSAH onset. 
 The definition of a poor outcome included a GOSE score of  ≤ 4 
and an mRS score of  ≥ 3. The exploratory endpoint was an assess-
ment of the occurrence of morbidity/mortality (M/M) events 
within 6 weeks after aSAH, which was a composite endpoint. An 
M/M event was defined as death for any reason, a vasospasm-re-
lated cerebral infarction, a vasospasm-related DIND, or the start 
of rescue therapy for vasospasm.
 A DIND was recorded based on different criteria depend-
ing on the availability of neurological assessment findings. For 
patients capable of undergoing neurological assessment, a DIND 
was confirmed based on a decrease of  ≥ 2 points on the modi-
fied Glasgow Coma Scale or an increase of  ≥ 2 points on the ab-
breviated National Institutes of Health Stroke Scale lasting for 
 ≥ 2 h. For patients whose neurological scores could not be as-
sessed, a DIND was recorded based on clinical findings suggest-
ing cerebral vasospasm (e.g., somnolence and fever) or, in 
the  absence of such findings when cerebral vasospasm was 
 observed on a DSA examination and rescue therapy was initi-
ated.
 Rescue therapy involved HHH therapy (hypervolemia, hyper-
tension, and hemodilution), percutaneous transluminal angio-
plasty, and intra-arterial administration of anti-platelet drugs (e.g., 
ozagrel) or vasodilators (e.g., fasudil hydrochloride, papaverine 
hydrochloride, and nimodipine) in the presence of moderate or 
severe vasospasm on DSA or clinical symptoms suggestive of va-
sospasm. 
 Pharmacokinetics 
 The aims of pharmacokinetics measurements were: (1) to com-
pare the plasma clazosentan concentration between the 5 mg/h 
and the 10 mg/h dose groups and (2) to compare differences in 
clazosentan pharmacokinetics between Japanese and Korean pa-
tients. Blood samples were collected at a steady state on day 9 ± 2 
after aSAH. The pharmacokinetics of clazosentan has previously 
been reported to be similar in Japanese and Caucasian patients 
 [13] .
 Safety 
 All adverse events that occurred between the start of the study 
drug administration and 24 h after discontinuation or completion 
of study treatment were recorded. Notable adverse events includ-
ing pulmonary complications, hypotension, and anemia were re-
corded from the start of study drug administration up to 6 weeks 
after aSAH onset. In addition, mortalities that occurred up to 12 
weeks after aSAH onset were recorded.
 Statistical Analysis 
 Sample size was calculated based on the phase 2a clinical trial 
with clazosentan  [14] and the occurrence of cerebral vasospasm in 
the CONSCIOUS-1 phase 2 dose-finding trial  [7] . It was set to the 
number of patients necessary to obtain a power of 0.9 at a 2-sided 
significance level of 5%. 
 The per-protocol set (PPS) was used for primary efficacy anal-
ysis in order to most reliably detect any dose-response relationship 
for the target population from whom valid data were available. 
Analysis was also conducted based on the all-treated set (ATS), 
which comprised patients who had received the study drug at least 
once and had undergone at least one efficacy evaluation after drug 
administration. The safety analysis group (safety set) included all 
patients who received at least one dose of study drug and under-
went at least one safety evaluation thereafter.
 Patients were assigned to groups by stratified randomization. 
The stratification factors were country (Japan vs. South Korea) and 
WFNS grade at the time of screening (I and II, vs. III and IV). The 
group assignment schedule was managed by a registration center 
and was not made known to anyone involved in the trial (except 
those involved in the work at the registration center) until unblind-
ing was done.
 Fisher’s exact test was used to assess the occurrence of cerebral 
vasospasm, and the Bonferroni-Holm method was used to adjust 
multiple testing. Patients with missing data were excluded from 
the analysis. In a sensitivity analysis to examine the effect of miss-
ing values, patients in whom the presence of cerebral vasospasm 
could not be determined by the IRC were assigned imputed find-
ings of “severe cerebral vasospasm.”
D
ow
nl
oa
de
d 
by
: 
Yo
ns
ei
 U
ni
ve
rs
ity
   
   
   
   
   
   
   
   
   
   
   
   
  
12
8.
13
4.
20
7.
84
 - 
7/
13
/2
01
7 
4:
46
:0
1 
AM
 Fujimura/Joo/Kim/Hatta/Yokoyama/
Tominaga 
Cerebrovasc Dis 2017;44:59–67
DOI: 10.1159/000475824
62
 The occurrence of cerebral infarction associated with vaso-
spasm within 6 weeks after aSAH onset, as well as GOSE and mRS 
scores, were assessed for a dose-response relationship using the 
Cochran-Armitage trend test. A Jonckheere-Terpstra test was con-
ducted to assess the results of the MMSEs. 
 Analysis of variance was used to assess differences in clazosen-
tan pharmacokinetics between countries and dose groups. 
 SAS ® software version 9.2 (SAS Institute, Cary, NC, USA) was 
used for conducting statistical analyses.
 Results 
 Patients 
 Patients were recruited for the trial from June 2009 to 
November 2010. Initially, 181 patients were enrolled. 
However, 2 patients were not administered the study 
drug because 1 patient withdrew consent and the other 
violated the inclusion/exclusion criteria. Therefore, the 
Baseline Moderate VS (day 8)
Baseline Severe VS (day 10)
a b
c d
 Fig. 2. Digital subtraction angiography images taken before and 
after the occurrence of moderate, severe cerebral vasospasm (VS). 
Patient 1 (aged 55 years): image taken ( a ) before clipping surgery 
and ( b ) 8 days after aneurysmal subarachnoid hemorrhage (aSAH) 
onset; spasm rate 34–65%. Patient 2 (aged 51 years): image taken 
( c ) before clipping surgery and ( d ) 10 days after aSAH onset; 
spasm rate:  ≥ 66%. Both patients received placebo. 
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ATS comprised 179 individuals ( Fig. 3 ). Of the patients 
who reached the drug administration stage of the study, 
one who was randomized to 5 mg/h clazosentan was ad-
ministered placebo during the entire treatment period in 
error. This patient was assessed as part of the 5 mg/h group 
in the ATS efficacy evaluation. In the safety set ( n = 179), 
this patient was assessed as part of the placebo group. The 
PPS comprised 158 patients ( Fig. 3 ). The most common 
2 reasons for patient exclusion from the PPS were inap-
propriate DSA imaging methodology and concomitant 
use of prohibited medications.
 In the placebo, 5 mg/h clazosentan, and 10 mg/h 
clazosentan groups, study drug administration was dis-
continued in 13.6% (8/59), 11.5% (7/61), and 6.8% (4/59) 
patients, respectively, mainly due to adverse events 
(13/19) or concomitant use of prohibited drugs (3/19).
 No significant differences in patient demographics 
were observed among the groups studied ( Table 1 ). 
 Efficacy 
 Moderate or severe cerebral vasospasm up to day 14 
after the onset of aSAH occurred in 80.0% of patients 
 inthe placebo group (95% CI 67.0–89.6), 38.5% in the 
5 mg/h clazosentan group (95% CI 25.3–53.0), and 35.3% 
in the 10 mg/h clazosentan group (95% CI 22.4–
49.9;  Fig. 4 ). Moderate or severe vasospasm was signifi-
cantly reduced with both doses of clazosentan (placebo 
vs. 5 mg/h clazosentan,  p < 0.0001; placebo vs. 10 mg/h 
clazosentan,  p < 0.0001; significance level 0.025 using the 
Bonferroni-Holm method). Findings from the ATS were 
supportive of the primary PPS analysis.
 The incidence of cerebral infarction associated with 
vasospasm up to 6 weeks after aSAH onset was 20.8% in 
the placebo group (95% CI 10.8–34.1), 3.8% in the 5 mg/h 
clazosentan group (95% CI 0.5–13.2), and 4.2% in the 
10  mg/h clazosentan group (95% CI 0.5–14.3;  Fig.  5 ). 
Compared with placebo, the incidence of cerebral infarc-
tion associated with vasospasm was significantly lower in 
both clazosentan groups (placebo vs. 5 mg/h clazosentan, 
 p = 0.0151; placebo vs. 10 mg/h clazosentan,  p = 0.0165). 
There were no significant differences in GOSE and mRS 
scores at 12 weeks after aSAH onset between either 
clazosentan dose group and the placebo group ( Fig. 5 ). 
The mean MMSE scores were identical across all 3 treat-
ment groups.
 The occurrence of M/M events was 47.3% in the pla-
cebo group (95% CI 33.7–61.2), 28.8% in the 5 mg/h 
clazosentan group (95% CI 17.1–43.1), and 14.3% in the 
10 mg/h clazosentan group (95% CI 5.9–27.2;  Fig.  6 ). 
 Statistical testing indicated significantly lower occurrence 
of M/M events in the 10 mg/h clazosentan group com-
pared with placebo ( p = 0.0003). M/M events are summa-
rized in  Figure 6 . The occurrences of vasospasm-related 
cerebral infarction and DIND, as well as the need for res-
cue therapy were significantly lower in the 10 mg/h 
clazosentan group compared with placebo ( Fig. 6 ).
Randomized to placebo (n = 60)
Study drug not received (n = 1)
Analyzed for ATS (n = 59)
Analyzed for PPS (n = 55)
H[FOXGHGIURPDQDO\VLV
²'6$LPDJHZDVLQDSSURSULDWH
²:LWKGUDZDORIFRQVHQW
²3URKLELWHGPHGLFDWLRQXVHG
Analyzed for PPS (n = 52)
H[FOXGHGIURPDQDO\VLV
   –  6 DSA image were inappropriate
²3URKLELWHGPHGLFDWLRQXVHG
²PLVXVHGVWXG\PHGLFDWLRQ
Analyzed for PPS (n = 51)
H[FOXGHGIURPDQDO\VLV
   –  7 DSA image were inappropriate
²3URKLELWHGPHGLFDWLRQXVHG
Analyzed for ATS (n = 61) Analyzed for ATS (n = 59)
5DQGRPL]HGWRFOD]RVHQWDQPJKn = 61) 5DQGRPL]HGWRFOD]RVHQWDQPJKn = 60)  Study drug not received (n = 1)
Randomized (n 
 Fig. 3. Patient disposition. Two placebo patients had more than one reason for exclusion from the PPS. ATS, 
 all-treated set; DSA, digital subtraction angiography; PPS, per-protocol set. 
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 Pharmacokinetics 
 Clazosentan pharmacokinetics was assessed in 111 pa-
tients. The plasma clazosentan concentration in the 5 and 
10 mg/h dose groups were 163.4 and 331.4 ng/mL, respec-
tively. There was no difference in plasma concentration 
between Japanese and Korean patients ( p = 0.2830). 
 Safety 
 Drug administration was discontinued due to adverse 
events in 8.3, 10.0, and 6.8% of the patients in the placebo, 
5 mg/h clazosentan, and 10 mg/h clazosentan groups, re-
spectively. No differences in the total numbers of adverse 
events were observed between the 3 treatment groups.
 Adverse events that were reported in 10 or more pa-
tients in all groups were cerebral vasospasm (56.7, 33.3, 
and 18.6% in the placebo, 5 mg/h clazosentan, and 
10 mg/h clazosentan groups, respectively) and headache 
(23.3, 21.7, and 25.4% in the placebo, 5 mg/h clazosentan, 
and 10 mg/h clazosentan groups, respectively). Lung 
complications were recorded in 11.7, 25.0, and 20.3% of 
patients in the placebo, 5 mg/h clazosentan, and 10 mg/h 
clazosentan groups, respectively. Hypotension was ob-
served in 0, 5.0, and 5.1%, respectively, and anemia was 
observed in 10.0, 18.3, and 13.6%, respectively. 
 The percentages of patients who had died by 12 weeks 
after aSAH onset were 1.7% in the placebo group (1 pa-
tient due to carotid artery occlusion and vasospasm), 
1.7% in the 5 mg/h clazosentan group (1 patient due to 
cerebral infarction), and 3.4% (2 patients due to cerebral 
infarction) in the 10 mg/h clazosentan group.
Table 1.  Patient demographics and disease characteristics
Placebo
(n = 59)
Clazosentan 5 
mg/h (n = 61)
Clazosentan 10 
mg/h (n = 59)
Total
(n = 179)
p value
Males, n (%) 29 (49.2) 19 (31.1) 19 (32.2) 67 (37.4) 0.076*
Age, years, mean ± SD 54.2±11.3 56.3±11.1 53.0±13.7 54.5±12.1 0.364**
0.323***
GCS, mean ± SD 13.5±2.1 13.7±1.9 13.5±2.2 13.6±2.1 0.981**
0.863***
WFNS grade, n (%) 0.996**
Grade 1 26 (44.1) 23 (37.7) 26 (44.1) 75 (41.9)
Grade 2 20 (33.9) 30 (49.2) 19 (32.2) 69 (38.5)
Grade 3 2 (3.4) 2 (3.3) 4 (6.8) 8 (4.5)
Grade 4 11 (18.6) 6 (9.8) 10 (16.9) 27 (15.1)
Time from aneurysm rupture to start 
infusion, h, mean ± SD 41.8±9.0 43.6±9.0 41.2±10.1 42.2±9.4 0.385**
Treatment duration, days, mean ± SD 11.5±2.2 11.4±2.5 11.9±1.7 11.6±2.2 0.594**
0.374***
Nimodipine (oral), n (%) 14 (23.7) 12 (19.7) 8 (13.6) 34 (19.0) 0.368*
Country, n (%) 0.969*
Japan 35 (59.3) 35 (57.4) 35 (59.3) 105 (58.7)
South Korea 24 (40.7) 26 (42.6) 24 (40.7) 74 (41.3)
 * Chi-square test; ** Kruskal–Wallis test; *** ANOVA.
Nimodipine (oral) was allowed for Korean patients only.
All treated set: patients who received at least one dose of study drug.
GCS, Glasgow Coma Scale; WFNS, World Federation of Neurosurgical Surgeons.
0
20
40
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100
Ev
en
t r
at
e,
 %
44
Placebo
(n = 55)
20
Clazosentan
5 mg/h
(n = 52)
18
Clazosentan
10 mg/h
(n = 51)
p < 0.0001*
p < 0.0001*
 Fig. 4. Moderate-to-severe cerebral vasospasm (per-protocol set). 
Statistical multiplicity was adjusted using the Bonferroni-Holm 
method. Fisher’s exact test (α = 0.025) was performed to assess the 
occurrence of cerebral vasospasm. 
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 Discussion 
 This study demonstrated, for the first time, that 
clazosentan prevents cerebral vasospasm and subsequent 
cerebral infarction after clipping surgery for aSAH in 
 Japanese and Korean patients. There were no statistically 
significant differences between the placebo and clazosen-
tan groups in GOSE and mRS scores 12 weeks after aSAH. 
These latter findings are in agreement with those previ-
ously reported in the CONSCIOUS-1, 2, and 3 trials with 
clazosentan  [7–9] . It was observed in this study that 
among the secondary and exploratory endpoints, the in-
cidence of cerebral infarction associated with vasospasm 
and the M/M events within 6 weeks after aSAH were sig-
nificantly reduced in the 10 mg/h clazosentan group com-
pared to the placebo group. This result was distinct from 
that of CONSCIOUS-2 where no significant difference in 
the incidence of M/M was observed between the placebo 
and the 5 mg/h clazosentan groups  [9] . Thus, it is con-
ceivable that the higher dose of clazosentan used in this 
study contributed, at least in part, to the favorable effect 
on cerebral infarction and M/M events after aSAH.
 The lack of statistically significant improvements in 
outcomes at 12 weeks despite the preventive effect of 
0
10
20
30
40
50
Ev
en
t r
at
e,
 %
26 15 7
Placebo
(n = 55)
Clazosentan
5 mg/h
(n = 52)
Clazosentan
10 mg/h
(n = 51)
p = 0.0729
p = 0.0003*
0
5
10
15
20
30
25
35
Ev
en
t r
at
e,
 %
1 0 1
Death
11 2 2
New cerebral
infarct
18 10 6
DIND
Vasospasm-related
15 7 3
Rescue therapy
p = 0.0151*
p = 0.0165*
p = 0.0113*
p = 0.0040*p = 0.1284
p = 0.0961
p = 1.0000
Placebo
Clazosentan 5 mg/h
Clazosentan 10 mg/h
a b
 Fig. 6. Exploratory endpoints ( a ) overall incidence of death and 
vasospasm-related morbidity (PPS), estimated using Fisher’s ex-
act test; ( b ) incidence of death and each component of vaso-
spasm-related morbidity (PPS),  estimated using Fisher’s exact 
test. PPS, per-protocol set; DIND, delayed ischemic neurological 
deficit. 
0
5
10
15
20
25
N
ew
 in
fa
rc
t, 
%
11
Placebo
(n = 55)
2
Clazosentan
5 mg/h
(n = 52)
2
Clazosentan
10 mg/h
(n = 51)
p = 0.0151*
p = 0.0165*
0
5
10
15
20
25
12
Placebo
(n = 55)
8 10
Clazosentan
5 mg/h
(n = 52)
10 mg/h
(n = 51)
p = 0.7654
GOSE 4, % mRS 3, %
0
5
10
15
20
25
12
Placebo
(n = 55)
8 9
Clazosentan
5 mg/h
(n = 52)
10 mg/h
(n = 51)
p = 0.5765
MMSE, mean
0
5
10
15
20
30
25
26.4
Placebo
(n = 55)
26.4 25.7
Clazosentan
5 mg/h
(n = 52)
10 mg/h
(n = 51)
p = 0.4159
a b
 Fig. 5. Secondary endpoints ( a ) incidence of vasospasm-related 
cerebral infarction (PPS), estimated using Fisher’s exact test; 
( b ) incidence of poor outcome (GOSE  ≤ 4, mRS  ≥ 3), estimated us-
ing the Cochran-Armitage trend test. Cognitive function (MMSE) 
at week 12 (PPS), estimated using the Jonckheere-Terpstra test. 
PPS, per-protocol set; GOSE, Glasgow Outcome Scale-Exten-
sion; mRS, modified Rankin Scale; MMSE, Mini-Mental State Ex-
amination. 
D
ow
nl
oa
de
d 
by
: 
Yo
ns
ei
 U
ni
ve
rs
ity
   
   
   
   
   
   
   
   
   
   
   
   
  
12
8.
13
4.
20
7.
84
 - 
7/
13
/2
01
7 
4:
46
:0
1 
AM
 Fujimura/Joo/Kim/Hatta/Yokoyama/
Tominaga 
Cerebrovasc Dis 2017;44:59–67
DOI: 10.1159/000475824
66
clazosentan on vasospasm could be related to a number 
of factors. First, the number of patients included in this 
study was not sufficient to conduct a prognostic evalua-
tion 12 weeks after aSAH onset. For instance, it has been 
reported that a sample size of over 5,000 patients is nec-
essary to fully evaluate drug efficacy based on mRS scores 
obtained up to 3 months after SAH onset  [15] . Second, 
the rate at which rescue therapy was employed in the 
placebo group was approximately twice as high as that in 
the 5 mg/h clazosentan group, and almost 4 times high-
er than that in the 10 mg/h clazosentan group. Therefore, 
it is conceivable that the higher use of rescue thera-
py  could have potentially compensated the deleterious 
effect of vasospasm especially in the placebo group, 
thereby diluting the treatment effect on the outcome at 
12 weeks. 
 This study was conducted exclusively in large-volume 
centers, where strong rescue therapies for vasospasm 
such as interventional angioplasty and/or intra-arterial 
vasodilator infusion are available almost all the time, but 
these are not treatments that can be easily or rapidly ad-
ministered at all medical facilities. Furthermore, intra-
arterial administration of a vasodilator could result in sys-
temic hypotension, especially when administered at high 
doses  [16, 17] , which are associated with a risk of deterio-
ration of the ischemic condition by vasospasm. Taken to-
gether with the high medical costs of rescue therapies 
 [18] , we believe that clazosentan could significantly con-
tribute to the management of vasospasm in patients with 
aSAH, not only in large-volume centers but also in gen-
eral clinical practice.
 It is noteworthy that the incidence of cerebral vaso-
spasm in this study was similar in both the 5 and 10 mg/h 
clazosentan treatment groups, while the incidence of 
DIND associated with vasospasm was significantly re-
duced in clazosentan-treated patients in a dose-depen-
dent manner. It has been reported previously that micro-
circulatory vasospasm and endothelial cell injury associ-
ated with platelet adhesion could participate in the 
development of DIND  [19] . It is therefore conceivable 
that treatment with 10 mg/h clazosentan in the current 
study further reduced the incidence of DIND by prevent-
ing the small-vessel vasospasm and/or blocking endothe-
lial cell damage. However, it has been reported that 
clazosentan might expand major arteries but not small 
peripheral vessels  [8] . A previous study has also suggested 
that an endothelin receptor antagonism could prevent 
vascular damage, endothelial dysfunction, and cerebral 
edema, and may lead to organ protection in hypertensive 
rats  [20] . Further investigation of cerebral hemodynam-
ics using positron emission tomography or single photon 
emission computed tomography could address this im-
portant issue.
 This study has 2 key limitations. First, only aSAH 
patients who underwent clipping surgery were includ-
ed, so it cannot robustly be determined whether these 
results can be reproduced in patients undergoing endo-
vascular coiling. Suzuki and Taki  [21]  reported no dif-
ference in the occurrence of symptomatic cerebral va-
sospasm after clipping and coiling procedures in pa-
tients with aSAH, and a previous 3-year follow-up 
study has shown no difference in prognosis after ei-
ther procedure  [22] . The effect of clazosentan on symp-
tomatic cerebral vasospasm after endovascular coiling 
therefore requires verification in future studies. Sec-
ond, we do not rule out the possibility that the inter-
pretation of the current study data could be affected in 
part by the fact that the primary efficacy analysis 
was based on the PPS. Nevertheless, findings from the 
ATS analysis confirmed the robustness of the primary 
analysis. 
 Conclusions 
 This clinical trial conducted in Japanese and Korean 
patients indicates that treatment with clazosentan at dos-
es of 5 or 10 mg/h can markedly decrease the occurrence 
of cerebral vasospasm following aSAH, and may improve 
outcomes after the onset of aSAH by preventing cerebral 
infarction. 
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